---
title: "Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287004510.md"
description: "Roivant Sciences Ltd.'s stock price target has been raised to $36.23, indicating a potential upside of 28%. The average target increased from $35.71, with estimates ranging from $29.5 to $41 per share. The consensus rating remains 'Buy' from 13 analysts, including 12 Buys and 1 Hold."
datetime: "2026-05-20T04:20:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287004510.md)
  - [en](https://longbridge.com/en/news/287004510.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287004510.md)
---

# Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside

-   According to estimates from 11 analysts, Roivant Sciences Ltd. stock's average price target has risen from $35.71 to $36.23, with forecasts ranging from $29.5 to $41 per share
-   Based on the May 19 closing price, the updated target implies approximately 28% potential upside
-   Consensus rating remains at “Buy” across 13 covering analysts, with 12 Buys, 1 Holds and 0 Sells

Explore more price target data and ratings for Roivant Sciences Ltd. on the , and track all previous and future analyst recommendations for Roivant Sciences Ltd. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)